Phaseline

Companies › Qanatpharma

Qanatpharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Cardiovascular; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lumacaftor
Cystic fibrosis transmembrane conductance regulator stabiliser
CFTRPhase 2Heart Failure With Reduced Ejection FractionMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07695090LumacaftorPhase 2Heart Failure With Reduced Ejection FractionCardiovascularMay 2027

Targets

CFTR (1)

Companies with the same targets

Vertex Pharmaceuticals Napo Pharmaceuticals 4D Molecular Therapeutics ReCode Therapeutics Napo Therapeutics Krystal Biotech Boehringer Ingelheim Arcturus Therapeutics

Companies built like this

Nyrada AllRock Bio Zomagen Biosciences Agiana Pharmaceuticals Cardurion Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.